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Purpose: The purpose of this study was to provide
a preliminary assessment of the safety, tolerability,
symptom control, and acceptability of buprenorphine-
naloxone buccal ﬁlm (BBN) for the maintenance
treatment of opioid dependence in patients converted
from buprenorphine-naloxone sublingual tablet or
ﬁlm (SLBN), as well as to determine the conversion
ratio for switching patients from SLBN to BBN.
Methods: This open-label study included adult
opioid-dependent subjects stabilized on 8/2 to 32/8
mg/d of SLBN for a minimum of 30 days. Study
subjects were converted to a bioequivalent dose of
BBN and maintained for 12 weeks.
Findings: A total of 249 subjects (mean age 38.7
years, 65.9% male) were converted from SLBN to a
single daily dose of BBN, and 79.1% completed the
12-week study. Adverse events and withdrawal symp-
toms led to discontinuation in 2.4% and 2.0% of
BBN-treated subjects, respectively. Rates of constipa-
tion reported at baseline declined from 41% just
before the initial BBN dose and within 24 hours of
the last SLBN dose to 13% after 12 weeks of BBN
treatment; treatment-emergent constipation was re-
ported by 2.8% of BBN-treated subjects. Oral mu-
cosal abnormalities were identiﬁed in 5% and 0.6% of
systematic oral examinations in SLBN- and BBN-
treated subjects, respectively. A total of 34 subjects
had Clinical Opiate Withdrawal Scale total scores
ranging from 10 to 25 (overall mean, 13.8) within 24
hours of taking their last SLBN dose, and scores for
these subjects were reduced to a range of 0 to 3
(overall mean, 0.7) at 3 hours after the initial dose of
BBN. Treatment compliance was high (108%); o1%
of urine samples were buprenorphine-free, and 92.4%
of BBN-treated subjects did not have a urine sample
that tested positive for a non-prescribed opioid. A1064total of 91.3% subjects rated the taste of BBN as
pleasant or neutral, and 82.5% rated BBN ease of use
as easy or neutral. The overall mean ﬁnal dose of BBN
was 8.0/1.4 mg/d, yielding a 2:1 buprenorphine
conversion ratio.
Implications: Although these results should be
considered preliminary due to the open-label design,
BBN was overall safe and well tolerated, and seemed
to provide adequate symptom control, in the treat-
ment of opioid-dependent subjects previously con-
trolled on SLBN for a minimum of 30 days. There
was good adherence to study medication and favor-
able patient acceptance of the buccal formulation. The
SLBN/BBN buprenorphine conversion ratio was 2:1.
ClinicalTrials.gov identiﬁer: NCT01666119. (Clin
Ther. 2015;37:1064–1075) & 2015 The Authors.
Published by Elsevier HS Journals, Inc.
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Opioid dependence is an important public health
problem that is associated with signiﬁcant morbidity
and mortality.1 In the United States, prescription
opioid misuse has been described as an epidemic,
with mortality now exceeding the combined rates
for suicide and motor vehicle accidents, as well
as the aggregate deaths from cocaine and heroin.2
Physicians can treat their opioid-dependent patients
with buprenorphine and ﬁxed combinations ofVolume 37 Number 5
Table I. Pharmacokinetic parameters for bupre-
norphine after use of 4.2/0.7–mg bupr-
enorphine-naloxone buccal film (BBN)
and 8/2–mg buprenorphine-naloxone
sublingual tablet (SLBN).
Parameter
BBN
4.2/0.7 mg
(n ¼ 65)
SLBN
Tablet 8/2 mg
(n ¼ 68)
Tmax, h
* 2.25 (0.75–4.00) 1.50 (0.50–2.75)
Cmax, ng/mL 3.41 (1.26) 3.06 (1.28)
AUC0–1,
ng*h/mL
27.17 (8.784) 28.67 (10.78)
J.G. Sullivan and L. Websterbuprenorphine-naloxone (BN) in brand-name sub-
lingual tablet and ﬁlm formulations (SLBN)* and
generic sublingual tablets. Despite evidence of their
effectiveness,3 the clinical utility of SLBN has been
compromised by concerns about diversion, nonmedical
use, and poor compliance with treatment.4–7 Other
concerns include challenges with palatability and tablet
dissolution times,6,8 which make it difﬁcult for some
patients to keep SLBN under their tongue, particularly
when attempting to talk or swallow. In addition,
talking while SLBN dissolves may affect the rate and
extent of absorption.9,10
BN buccal ﬁlm (BBN),† a novel transmucosal
BN product, is a small, thin, bilayered dissolvable
ﬁlm that adheres to the buccal mucosa and uses Bio-
Erodible MucoAdhesive (BEMA; BioDelivery Sciences
International, Inc, Raleigh, North Carolina) drug
delivery technology to optimize BN administration
and patient convenience. BEMA delivery technology is
composed of ﬂexible water-soluble polymeric ﬁlms.
The mucoadhesive side contains the active ingredient
buprenorphine and adheres to the moist buccal mu-
cosa upon contact; the backing layer facilitates uni-
directional buprenorphine absorption into the buccal
mucosa, isolating the buprenorphine from saliva and
limiting the amount of buprenorphine swallowed into
the gastrointestinal tract. Because the ﬁlm completely
dissolves, there is no residual ﬁlm to remove.
In pharmacokinetics (PK) research with the buccal
formulation using BEMA technology, buprenorphine
exposure was linear across doses of 0.9, 3.5, and
5.25 mg, and the Cmax and the AUC values for
buprenorphine with a single 3.5/0.6–mg ﬁlm were
comparable to the equivalent dosage administered as
four 0.875/0.15–mg ﬁlms. These ﬁndings, which
suggested that buprenorphine exposure with BBN
3.5/0.6 mg would be similar to SLBN 8/2 mg with
no greater exposure to naloxone, provided the ration-
ale for the conversion dose in the current study.
Meanwhile, to determine the bioavailability of BBN
4.2/0.7 mg relative to SLBN 8/2–mg tablets and to
demonstrate bioequivalent buprenorphine exposure
and equal or lower naloxone exposure for BBN
4.2/0.7 mg relative to SLBN 8/2–mg tablets, an*Trademark: Suboxones (Reckitt Benckiser plc, Parsippany,
New Jersey).
†Trademark: Bunavail® (BioDelivery Sciences International,
Inc, Raleigh, North Carolina).
May 2015open-label, single-dose, crossover PK study in 80
healthy naltrexone-blocked volunteers was performed.11
Buprenorphine exposure from BBN 4.2/0.7 mg was
bioequivalent to an 8/2–mg SLBN tablet (Table I).
Based on the comparable buprenorphine bioavailability
and allowing for dosage adjustments, the current open-
label study provides a preliminary assessment of the
tolerability, symptom control, and patient acceptance
with BBN and conﬁrms the most appropriate conversion
ratio between BBN and SLBN.
SUBJECTS AND METHODS
Subjects
This open-label study was approved by the Coper-
nicus Group institutional review board on June 20,
2012, and was conducted between August 6, 2012,
and January 8, 2013, at 10 study centers located in
the United States. Study subjects included individuals
diagnosed with opioid dependence according to the
criteria of the Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition, Text Revision, who
had been maintained on a stable daily dose (8–32 mg)
of SLBN for a minimum of 30 days. Subjects were
eligible for inclusion if they were adults aged 18 to 65
years (women of childbearing potential who were not
pregnant or breastfeeding and were using an accept-
able method of birth control) who had been diagnosed
with opioid dependence or addiction in the past
12 months; had a positive urine buprenorphine andt½, h 27.53 (11.99) 28.67 (12.82)
*Median (range). Unless otherwise indicated, values are
given as mean (SD)
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Clinical Therapeuticsnorbuprenorphine test at screening; and were in good
general health, with no clinically signiﬁcant ﬁndings
on medical history, physical examination, clinical
laboratory tests, and ECG.
Subjects were excluded if they had serum potassium
r3.0 mEq/L or serum magnesium r1.0 mg/dL
with no cardiac history or symptomatic arrhythmia;
class III or IV congestive heart failure; symptomatic
myocardial ischemia; a family or personal history of
long QT syndrome; uncontrolled hypertension; a
history of hypersensitivity, allergy, or intolerance to
buprenorphine, naloxone, or related drugs; a history
or current evidence of any clinically signiﬁcant dis-
order or any other condition that would jeopardize
the safety of the subject or impact the validity of the
study results; a pierced tongue or mouth; or any
clinically signiﬁcant abnormality of the buccal mucosa
that could affect drug absorption. Also excluded were
those with serum creatinine, alanine aminotransferase,
or aspartate aminotransferase values Z3 times the
upper limit of normal; pulse oximetry r93% at
baseline; clinically signiﬁcant abnormality on 12-lead
ECG; moderate to severe hepatic impairment (Child-
Pugh); or a positive urine toxicology screen for non-
prescribed medications or drugs of abuse. Subjects
were also excluded who had used an investigational
drug or device or taken class IA or class III antiar-
rhythmic medications, or any medication, nutraceut-
ical, or herbal product with cytochrome P450 3A4
inhibition or induction properties within the last 30
days; participated in a previous clinical study of BBN;
or were judged to be a suicidal risk (history of suicidal
ideation or suicidal behavior r3 months before
baseline).
For all 10 study centers, informed consent was
obtained from eligible subjects before any assessments
were conducted, in accordance with written consent
guidelines and the mandates of Good Clinical Practice
and the Declaration of Helsinki.12
Study Design
Eligible subjects were converted to an approxi-
mately equivalent dose of BBN (based on earlier
BBN PK studies11), with subsequent dose adjust-
ments as clinically indicated to control opioid
withdrawal symptoms or adverse events (AEs).
Subjects were closely monitored for evidence of oral
mucosal AEs attributed to the application of the BBN
ﬁlm. The total duration of participation for each1066subject was up to 18 weeks and included a screening
period (subjects continued to take SLBN tablets or
ﬁlms), a baseline visit (the day after discontinuing
SLBN; received the ﬁrst dose of BBN), and a 12-week
open-label treatment period with BBN ﬁlms. Vital
signs, AEs, risk of suicide, oral mucosa, and concom-
itant medications were regularly assessed throughout
the study. Clinical Opiate Withdrawal Scale (COWS)
assessments, pulse oximetry, clinical laboratory tests,
urine toxicology screening, urine buprenorphine and
norbuprenorphine testing, pregnancy testing, and
12-lead ECGs were also conducted. At the end of
the 12-week treatment period, subjects resumed their
previous SLBN treatment and had a follow-up visit
1 week later.
A training program to standardize the oral mucosa
examination was developed by a board-certiﬁed den-
tist, who trained clinical investigators on the oral
examination process by using a standardized protocol.
The examination procedure followed a systematic
assessment of the subject’s mouth, with the left and
right sides divided by a midline from the corner of the
mouth to the tonsillar pillar, resulting in 4 quadrants.
Each quadrant was assessed as normal or abnormal,
and the following terms were used to describe the
ﬁndings: 0 ¼ normal, 1 ¼ redness, 2 ¼ swelling or
raised lesions, 3 ¼ ulceration, 4 ¼ bleeding, and 5 ¼
other. Any abnormalities, including pain, were re-
corded as AEs. Participating investigators were re-
quired to demonstrate proﬁciency in identiﬁcation and
classiﬁcation of observations by testing before en-
rolling subjects. Oral examinations were performed
at screening, baseline, and 5 additional times during
the 12-week treatment period.
Subjects were monitored for clinical control of their
opioid dependence in accordance with the Clinical
Guidelines for the Use of Buprenorphine in the Treat-
ment of Opioid Addiction: A Treatment Improvement
Protocol for the use of buprenorphine in the manage-
ment of opioid dependence.13 These guidelines
included urine assessments for non-prescribed opioids
as well as for buprenorphine and norbuprenorphine.
Dose adjustments were permitted with this protocol as
in standard clinical practice, but subjects were in-
structed to use BBN once daily regardless of their
preference for SLBN dosing frequency.
At baseline (within 24 hours after discontinuation
of SLBN and before initiating BBN dosing), a bupre-
norphine/naloxone–associated symptom checklist wasVolume 37 Number 5
J.G. Sullivan and L. Webstercompleted to enable assessment of any changes in
symptoms while undergoing BBN treatment. Regard-
less of the symptom checklist, any symptom that was
new or considered a worsening of a pre-existing
symptom during the study was reported as an AE.
The same checklist was completed again at day 84,
and a comparison of symptom incidence was then
performed. In addition, COWS scores and pulse
oximetry were measured just before the ﬁrst dose
of BBN and 3 hours after the dose to assess for signs
of withdrawal and respiratory depression. Beginning
on day 2 (24 hours after the initial BBN dose and
continuing throughout the remainder of the 12-week
study), “opioid withdrawal syndrome” was recorded as
an AE for subjects who experienced any symptoms that
investigators considered opioid withdrawal.Treatments
BBN ﬁlm doses of 3.5/0.6–mg and 5.25/0.9–mg
BN were provided for the study, with an initial
conversion ratio of BBN 3.5/0.6 mg to an 8/2–mg
SLBN tablet.11 Regardless of the daily dose
frequency of SLBN administration before the study,
subjects started once-daily dosing with BBN at the
dose that most closely approximated their total
daily buprenorphine exposure from SLBN tablets
or ﬁlms (Table II). Study personnel instructed
subjects on the appropriate application of the BBN
ﬁlm and administered the initial dose of BBN.
When multiple buccal ﬁlms were required to
achieve the target dose, subjects applied the BBN
ﬁlms simultaneously to the inside of each cheek, with
no more than 2 ﬁlms applied on a single side.Table II. Initial conversion of buprenorphine-
naloxone sublingual tablet or film
(SLBN) to buprenorphine-naloxone buc-
cal film (BBN).
Current SLBN
Dose, mg
Initial BBN
Dose, mg
8/2 1  3.5/0.6
12/3 1  5.25/0.9
16/4 2  3.5/0.6
24/6 2  5.25/0.9
32/8 4  3.5/0.6
May 2015Assessments
Safety assessments included use of concomitant
medications, opioid withdrawal (COWS), urine tox-
icology screen, urine buprenorphine and norbupre-
norphine screen, electronic Columbia Suicide Severity
Rating Scale (eC-SSRS), urine pregnancy test, stand-
ardized oral examination, physical examination, vital
signs, pulse oximetry, ECGs, clinical laboratory tests
(including hematology, blood chemistry, and urinal-
ysis), and AEs. Evidence of symptom control included
COWS scores after the ﬁrst dose of BBN, urine opioid
testing, and retention of subjects in the study.
The AE verbatim text was coded and classiﬁed
according to system organ class and preferred term by
using the Medical Dictionary for Regulatory Activities
version 12.0 (March 2009). An AE was considered
treatment-emergent if the onset date was on or after
the ﬁrst dosing date or was missing. AEs classiﬁed as
possibly related, probably related, or undesignated
were considered drug related. All serious AEs were
collected from the start of study drug administration
and were followed up by the investigator until they
resolved or stabilized, the subject was lost to follow-
up, the event was otherwise explained, or 30 days had
passed since the last dose of study drug. Serious
treatment-emergent AEs and drug-related serious
treatment-emergent AEs were summarized according
to system organ class and preferred term from the
Medical Dictionary for Regulatory Activities. Subjects
withdrawn due to AEs were identiﬁed on the elec-
tronic case report form as “Action Taken ¼ Study
Drug Discontinued”. Abnormal physical examination
ﬁndings at day 84 that were not present at screening
or baseline were recorded as AEs.
Clinical laboratory tests were performed at screen-
ing; baseline; and days 28, 56, and 84 or early
termination. Vital signs (seated blood pressure, heart
rate, respiratory rate, and pulse oximetry) and oral
temperature were recorded according to the schedule
of assessments, as were normal and abnormal ECG
ﬁndings at screening and day 84. Concomitant med-
ication was coded and classiﬁed by using the World
Health Organization Drug Dictionary (June 2009).
To measure opioid withdrawal, the COWS total
score (including subscales for pulse rate, gastrointes-
tinal upset, sweating, tremor, restlessness, yawning,
pupil size, anxiety or irritability, bone or joint aches,
gooseﬂesh skin, runny nose, or tearing) was assessed
before the ﬁrst dose of BBN and at 3 hours’ post-dose.1067
Clinical TherapeuticsThe score was calculated as the sum of all subscales
for each subject at each scheduled time.
At a minimum, the following drugs were screened
in urine: amphetamines, benzodiazepines, barbitu-
rates, cannabinoids, cocaine, and opiates. Although
a negative urine toxicology result (excluding pre-
scribed medications) must have been obtained at
screening for a subject to be eligible for study enroll-
ment, a positive cannabinoid result was not necessa-
rily considered exclusionary if the subject had been
counseled and, in the opinion of the investigator, was
reliable. Positive urine toxicology results after baseline
were handled at the discretion of the investigator.
Analysis of samples negative for non-prescribed
opioids was used as a measure of symptom control.
Treatment compliance was assessed by using return
ﬁlm counts and urine testing for buprenorphine and
norbuprenorphine. Subjects with post-baseline nega-
tive results for either analyte at 2 consecutive visits
were discontinued from the study for noncompliance.
Study drug compliance was calculated as follows: [total
amount of study drug (number of ﬁlms) taken or
reported as lost by subject/total amount of study drug
(number of ﬁlms) prescribed]  100 ¼ % compliance.
Mean compliance was also calculated assuming that
study drug reported as “lost” was not taken by the
subject. A former US Drug Enforcement Administration
agent, retained as a consultant, assisted in the creation
of a drug diversion reporting policy, addressed Drug
Enforcement Administration accountability and report-
ing requirements at the investigator’s meeting, and
contributed to the creation of site- and subject-level
study drug accountability forms.
To assess a subject’s risk of suicide, the eC-SSRS
was administered. Two versions of the eC-SSRS were
used and electronically scored: the “baseline” version
to assess lifetime suicidal ideation and behavior, and
the “since last visit” version to assess suicidality since
the subject’s last study visit.
To determine the acceptability of the novel dose form,
subjects rated BBN ﬂavor and ease of use by using
5-point categorical scales. BBN was rated on a scale of
very pleasant to very unpleasant. Likewise, BBN ease of
use was rated on a scale of very easy to very difﬁcult.
RESULTS
Subject Characteristics
Four hundred subjects were assessed for eligibility,
and 151 were excluded from further participation.1068A total of 249 subjects stabilized on 8/2 to 32/8 mg of
SLBN (105 on tablets and 144 on ﬁlms) were enrolled,
converted to a once-daily dose of BBN, and included
in the safety population; 79.1% of subjects (107
subjects receiving SLBN ﬁlms and 90 subjects receiv-
ing SLBN tablets) completed the study. Figure 1
summarizes the disposition of subjects. The mean
duration of treatment was 73.8 days. Of the 52
(20.9% of 249) subjects who discontinued parti-
cipation in the study before 12 weeks had elapsed, 5
(2.0%) discontinuations were due to drug withdrawal
symptoms. Demographic and baseline characteristics
are shown in Table III. Notably, 43% of subjects had
concurrent musculoskeletal or connective tissue
disease, which suggests the potential presence of
concomitant pain symptoms, and 40.2% of SLBN-
treated subjects had concurrent gastrointestinal
disorders.
Safety and Tolerability
A total of 192 subjects (77.1%) experienced a
treatment-emergent AE, and 130 subjects (52.2%)
had an AE that was considered possibly drug related,
drug related, or had data missing. There were no
deaths; 2 (0.8%) subjects had serious AEs, and 11
(4.0%) subjects were withdrawn from the study due
to an AE, including 5 subjects experiencing with-
drawal symptoms. There were no clinically signiﬁcant
changes in vital signs and no changes in mean ECG
parameters across the study period.
Oral mucosal abnormalities were identiﬁed in
6.8% (17 of 249) of SLBN-treated subjects before
initiating BBN dosing and in 2.4% (6 of 249) of
subjects treated with BBN over 12 weeks. Of the
6 subjects with abnormalities identiﬁed over the
12 weeks of treatment, 3 (1.2%) subjects had mucosal
redness on oral examination that was considered drug
related. Each of these oral events was mild in severity
and resolved with continued BBN administration. No
oral mucosal abnormalities were detected on day 14
or from day 56 through the end of the study period
(Figure 2).
A checklist of typical BN symptoms was provided
to all participating subjects; 186 subjects completed
the checklist at baseline and day 84. Of these subjects,
76 (40.9%) reported constipation at the time of SLBN
discontinuation but before treatment with BBN, and
24 (12.9%) subjects reported constipation after 12
weeks of BBN treatment, a decline of 68% (52 of 76)Volume 37 Number 5
Converted to BBN (n = 249)
Discontinued (n = 52)
Adverse event (n = 6)
Recurrence of drug abuse (n = 2)
Suicidal ideation
Mouth ulceration
Osteomyelitis
Headache
Withdrawal symptoms (n = 5)
Withdrew consent (n = 16)
Nonstudy-related reasons (n = 8)
Previously experienced withdrawal symptoms (n = 4)
Transportation issues
Wanted to go back on SLBN
Hesitant to disclose details of lost dose
Scheduling issues
Lost to follow-up (n = 7)
Other (n = 7)
Elevated creatinine at baseline
Noncompliance with study medication/visit schedule
Disallowed anticonvulsant (topiramate)
Disallowed barbiturate or amphetamine
Uncontrolled diabetes
Pregnancy
Did not return after day 84 for the follow-up visit
Moved from area
Completed (n = 197)
Assessed for eligibility (N = 400)
Excluded (n = 151)
Figure 1. Subject disposition. BBN ¼ buprenorphine-naloxone buccal film; SLBN ¼ buprenorphine-naloxone
sublingual tablets or films.
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emergent constipation was reported by 2.8% (7 of 249)
of subjects over the course of the study.
Beginning on day 2, for those subjects who re-
ported at least 1 symptom that was considered opioid
withdrawal by the investigator, “opioid withdrawal
syndrome” was recorded as the AE (Table IV). The
majority of subjects did not have an AE of opioid
withdrawal syndrome (64.3%). Of the 89 subjects
who experienced withdrawal syndrome, most exper-
ienced mild events (85.4%), and the majority of thoseMay 2015required 0 or 1 BBN dose adjustment to abate the
symptom. None was judged to be severe. The majority
of dose adjustments occurred during the ﬁrst 4 weeks
of treatment, and most of these events resolved with a
single adjustment.
Drug dependence, a term resulting from the coding
of verbatim AEs containing the word “craving”, was
considered drug related in 2.4% (6 of 249) of subjects.
Events considered possibly, probably, or deﬁnitely
related to BBN that occurred in 42 subjects are
summarized in Table V.1069
Table III. Demographic and baseline charac-
teristics of study subjects.
Characteristic Value
Age, y, mean (minimum,
maximum)
38.7
(20.0, 62.0)
Sex, no. (%)
Male 164 (65.9)
Female 85 (34.1)
Current medical conditions/
disorders, no. (%)*
Psychiatric† 249 (100.0)
Nervous system 112 (45.0)
Musculoskeletal or connective
tissue
107 (43.0)
Gastrointestinal 100 (40.2)
Immune system 65 (26.1)
Cardiovascular 58 (23.3)
Hepatobiliary 46 (18.5)
Reproductive system and breast 35 (14.1)
Respiratory, thoracic, and
mediastinal
32 (12.9)
Skin and subcutaneous tissue 32 (12.9)
Endocrine 27 (10.8)
Prior medication usage, no. (%)‡
SLBN 249 (100)
Clonazepam 23 (9.2)
Trazodone 21 (8.4)
Ibuprofen 18 (7.2)
Amphetamine mixed salts 17 (6.8)
Alprazolam 16 (6.4)
Gabapentin 15 (6.0)
Lisinopril 15 (6.0)
Zolpidem tartrate 14 (5.6)
SLBN ¼ buprenorphine-naloxone sublingual tablet
or ﬁlm.
*Reported in 410% of subjects.
†The most common psychiatric conditions were opioid
dependence, anxiety, and depression.
‡Used by 45% of subjects.
Clinical TherapeuticsEvidence of Efficacy
At baseline (before BBN dose administration and
within 24 hours of taking the last SLBN dose), COWS
scores ranged from 0 to 25, with an overall mean of
3.3 in the total population and 4.6 in subjects taking1070SLBN 16, 24, or 32 mg daily. Three hours after the
initial BBN dose, the overall mean COWS score was
r0.54 for the study population. Among subjects with
baseline COWS scores ranging from 10 to 25 (n ¼ 34)
after discontinuation of SLBN, initiation of BBN
resulted in a decline in mean scores from Z13.1 to
r1.1 in 3 hours (Table VI). These results depend on
the bioequivalence of buprenorphine exposure from
BBN 4.2/0.7 mg and an 8/2–mg SLBN tablet, which
was demonstrated in the previously conducted PK
study,11 and should be considered preliminary due to
the open-label design of this study.
Compliance with study drug administration (per
protocol) was high; mean study drug compliance was
108% when study drug reported by the subject as
“lost” was considered as “taken.” During the 12-
week BBN administration period, 11 subjects had
buprenorphine-negative urine samples, and 11 sub-
jects had norbuprenorphine-negative urine samples
(Table VII). One subject had negative results for
both, recorded at the day 84 visit. No subject had
multiple buprenorphine-negative samples. Urine testing
was positive for a non-prescribed opioid in 19 (7.6%)
subjects during the BBN dosing period (Figure 4).
Eleven of these 19 subjects had a single opioid-
positive urine sample, 4 had 2 opioid-positive urine
samples, and 4 had 42 opioid-positive urine samples.
The mean SLBN dose at the time of study entry was
15.74 mg of buprenorphine per day. Based on an
initial conversion factor of BBN 3.5/0.6 mg ¼ SLBN
8/2 mg, the mean BBN starting dose was 6.9/1.2 mg/d.
The starting conversion dose of BBN administered as
a once-daily dose was adequate for 63.5% (158 of
249) of subjects regardless of their previous SLBN
dosing regimen. After dose adjustments (Table VIII),
the mean ﬁnal dose of BBN was 8.0/1.4 mg, yielding a
2:1 buprenorphine conversion ratio from SLBN 16 mg
to BBN 8.0 mg. The established conversion ratio is
further supported by the higher relative bioavailability
demonstrated in the PK study comparing BBN 4.2/0.7
mg with SLBN 8/2 mg.11
Treatment Acceptance
The majority (91.3%) of subjects considered the
ﬂavor of BBN to be very pleasant, pleasant, or neutral,
and a similarly high proportion (82.5%) rated BBN as
very easy, easy, or neutral for ease of use (Figure 5).
The assessments of the ﬂavor and ease of use of
BBN that were favorable or neutral were reportedVolume 37 Number 5
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N 249 249 209 204 219 206 199 36
Redness 2 5 0 0 3 0 0 0
Swelling 13 2 1 0 1 0 0 0
Ulceration 1 0 0 0 0 0 0 1
Bleeding 0 0 0 0 0 0 0 0
Other 1* 1† 0 0 0 0 0 0
BBN
SLBN
BBN
Figure 2. Subjects with abnormal oral examination results after treatment with buprenorphine-naloxone
sublingual tablets or films (SLBN) or buprenorphine-naloxone buccal film (BBN).
*Small, 1-mm mucus cyst (benign) in the upper right mucosa. †Tiny white spot in the upper right
mucosa; white adherent patch in the upper left mucosa. ET ¼ early termination.
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Figure 3. Constipation at the end of treatment
with buprenorphine-naloxone sublin-
gual tablets or films (baseline) and
week 12 in subjects* converted to
buprenorphine-naloxone buccal film
(n ¼ 186).
*A total of 186 subjects completed the
symptom checklist at baseline and
week 12. ET ¼ early termination.
Table IV. Subjects with treatment-emergent drug
withdrawal syndrome* grouped accord-
ing to severity and required dose
adjustments (N ¼ 249).
Dose
Adjustment†
Subjects With Drug Withdrawal
Syndrome, no. (%)
Absent‡ Mild Moderate Severe
0 136 (54.6) 16 (6.4) 5 (2.0) 0
1 20 (8.0) 44 (17.7) 5 (2.0) 0
2 4 (1.6) 16 (6.4) 3 (1.2) 0
*Recorded as an adverse event if the subject experienced
Z1 symptom considered to be opioid withdrawal.
†Required after initial conversion from buprenorphine-
naloxone sublingual tablet or ﬁlm.
‡Drug withdrawal syndrome not reported.
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Table V. Treatment-emergent adverse events
occurring in 45% of subjects
(N ¼ 249).
Event No. (%)
Lethargy 22 (8.8)
Headache 20 (8.0)
Nasopharyngitis 14 (5.6)
Table VII. Buprenorphine- and norbu-
prenorphine-negative urine sam-
ples among subjects treated with
buprenorphine-naloxone buccal
film (N ¼ 249).
Visit
Buprenorphine Norbuprenorphine
N No. (%) N No. (%)
Screening 249 1 (0.4) 249 1 (0.4)
Baseline 247 3 (1.2) 244 3 (1.2)
Day 7 237 0 237 6 (2.5)
Day 14 228 2 (0.9) 227 2 (0.9)
Day 28 218 1 (0.5) 217 4 (1.8)
Day 42 211 1 (0.5) 210 1 (0.5)
Day 56 204 1 (0.5) 204 1 (0.5)
Day 70 198 3 (1.5) 196 2 (1.0)
Day 84 197 1 (0.5) 197 3 (1.5)
ET 37 2 (5.4) 35 1 (2.9)
Total 15 24
ET = early termination
Clinical Therapeuticsirrespective of whether subjects were switched from
SLBN tablets or ﬁlms.
DISCUSSION
Overall, BBN showed an acceptable safety and toler-
ability proﬁle in this 12-week study for the mainte-
nance treatment of opioid dependence in subjects
previously stabilized for at least 30 days on 8- to
32-mg buprenorphine tablets or ﬁlms. With each of
the 10 participating investigators applying a stand-
ardized protocol of oral mucosal examination, the
64% decline in subjects experiencing abnormalities
over the BBN dosing period indicates a low risk for
clinically signiﬁcant oral mucosal abnormalities due to
BBN administration over 12 weeks. These results
address the oral tolerability of the novel buccal ﬁlm
formulation (ie, oral mucosal irritation) and align withTable VI. Clinical Opiate Withdrawal Scale total score fo
BBN initial dose, mg 3.5/0.6 5.25/0.9
Prior SLBN daily dose
mg, no. (%)
8 (0) 12 (1)
Predose mean (range) — 13.0 (13 to 13) 13.8
3 Hours’ post-dose
mean (range)
— 1.0 (1 to 1) 1.
Change from baseline
to 3 hours; postdose
mean (range)
— –12.0 (–12 to –12) –12.7
BBN ¼ buprenorphine-naloxone buccal ﬁlm; SLBN ¼ buprenor
*2  3.5/0.6 mg.
†2  5.25/0.9 mg.
‡4  3.5/0.6 mg.
1072previous research showing that the BEMA technology
provides acceptable buccal safety and rapid, consistent
drug absorption, even in the presence of oral
mucositis.14
The constipation rate reported at baseline, after
the last dose of SLBN, was 460%, and subjectsr subjects with a baseline total score Z10 (n ¼ 34).
7.0/1.2* 10.5/1.7† 14.0/2.3‡
16 (15) 24 (16) 32 (2)
(10 to 25) 13.8 (10 to 23) 14.5 (11 to 18)
1 (0 to 3) 0.6 (0 to 3) 0 (0 to 0)
(–25 to –9) –13.3 (–22 to –10) –14.5 (–18 to –11)
phine-naloxone sublingual tablet or ﬁlm.
Volume 37 Number 5
01
2
3
4
4
3 3 3
8 8 8
6 6 6
5 5 5
0 0
7 7 7
5
6
7
8
9
Baseline Day 7 Day 14 Day 28 Day 42 Day 56 Day 70 Day 84 ET
Rx + non-Rx Non-Rx
247 237 228 218 211 204 198 197 37N
O
pi
oi
d-
po
si
tiv
e 
U
rin
e 
Sa
m
pl
es
Figure 4. Number of opioid-positive urine sam-
ples during treatment (Rx) with bupre-
norphine-naloxone buccal film (N ¼
249). ET ¼ early termination.
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Figure 5. Subject assessment of buprenorphine-
naloxone buccal film flavor and ease of
use after switching from buprenor-
phine-naloxone sublingual tablets or
films (SLBN).
J.G. Sullivan and L. Websterexperienced a substantial decrease after being switched
to BBN. The novel buccal formulation might have had
a role in reducing constipation, possibly due to less BN
reaching opioid receptors in the gastrointestinal tract as
a result of increased bioavailability and lower total
buprenorphine dose. This positive ﬁnding must be
interpreted with caution due to the open-label nature
of the study.Table VIII. Dose adjustments in buprenorphine-naloxone
Variable 3.5/0.6 5.25/0.9 7.0/1
Starting dose, mg
3.5/0.6 (n ¼ 48) 29 (60.4)* 8 (16.7) 9 (1
5.25/0.9 (n ¼ 40) 0 27 (67.5)* 10 (2
7.0/1.2 (n ¼ 110) 0 0 68 (6
10.5/1.7 (n¼43) 0 1 (2.3) 0
14.0/2.3 (n¼8) 0 0 0
Total no. of patients 29 36 8
No. of dose adjustments 0 9 1
Average starting dose,
6.9/1.2 mg
Aver
*Patients whose starting and ﬁnal buprenorphine-naloxone buc
May 2015The COWS total score reductions in subjects with
baseline values Z10, high retention rate, and low
incidence of opioid-positive urine samples suggest that
an average daily dose of 8.0/1.4 mg of buprenorphine
may be effective in subjects previously stabilized on a
mean daily dose of 15.74 mg of buprenorphine.
Despite stable COWS scores at 3 hours after the
initial BBN dose, however, some BBN-treated subjectsbuccal film (BBN). Values are given as number (%).
Final Dose, mg
.2 10.5/1.7 14.0/2.3 10.5/1.7 21.0/3.6
8.8) 2 (4.2) 0 0 0
5.0) 3 (7.5) 0 0 0
1.8)* 32 (29.1) 3 (2.7) 5 (4.5) 2 (1.8)
26 (60.5)* 6 (14.0) 10 (23.3) 0
0 8 (100.0)* 0 0
7 63 17 15 2
9 37 9 15 2
age final dose, 8.0/1.4 mg
cal ﬁlm doses were the same (ie, no dose adjustment).
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Clinical Therapeuticsreported symptoms of drug withdrawal syndrome.
This outcome may have been due to the change in
dosing frequency or the slightly lower buprenorphine
exposure from the initially chosen conversion ratio.
However, a high level of compliance with BBN
treatment was demonstrated by the nearly 80% of
subjects who completed the 12-week study, as well as
by the urine test results for buprenorphine and
norbuprenorphine.
Subjects in this study who were converted to BBN
reported high ratings for acceptability, and a large
percentage of subjects who switched from SLBN
tablets or ﬁlms considered BBN easy to use. This
ﬁnding corroborates previous research, in which 85%
of subjects who used the BEMA technology rated it as
excellent, good, or very good.15 Because the favorable
ratings were provided by subjects switched from
SLBN tablets or ﬁlms, it seems unlikely that the
previous SLBN formulation will be an important
factor in the decision to convert patients to BBN.
In these opioid-dependent subjects, the mean ﬁnal
effective dose of BBN was 50% less than the
baseline dose of SLBN. This parallels PK ﬁndings in
healthy volunteers, in which BBN provided buprenor-
phine exposure equivalent to SLBN tablets at approx-
imately one half the dose, with reduced exposure to
naloxone.11 The near-identical results across different
cohorts demonstrate the consistency of buprenorphine
delivery with the BEMA technology and suggests that,
in clinical practice, switching patients to BBN should
be safe and predictable.
SLBN has been widely used and is generally
considered safe and effective,3 but sublingual admin-
istration has been a concern due to suboptimal
dissolve times, inconsistent absorption, risk of div-
ersion, and unintentional exposure in children.4–7 By
permitting the use of a lower BN dose than sublingual
tablets and ﬁlms, BBN may help to control the
symptoms of opioid dependence with a potentially
lower incidence of adverse effects, favorable ease of
administration, and high rate of adherence.11,16,17
Both active ingredients have a bitter taste, but the
current study suggests that BBN may address this
challenge: the majority of subjects switched from
SLBN considered BBN to be pleasant-tasting.
This study has some limitations due to its open-
label design. First, it is possible that not blinding
investigators might have inﬂuenced their assessments.
In addition, the ﬁndings of symptom control that are1074suggestive of efﬁcacy must be considered as prelimi-
nary. Despite these shortcomings, in opioid-dependent
subjects treated with a stable dose of 8- to 32-mg
buprenorphine daily for at least 30 days, BBN
exhibited evidence of safety and tolerability, with a
low rate of treatment-emergent AEs. Preliminary
efﬁcacy, speciﬁcally COWS scores after ﬁrst dose,
urine opioid testing, and retention over the course of
the 12-week study, was also demonstrated. The 2:1
buprenorphine dose conversion ratio from the mean
baseline SLBN dose to the mean BBN dose at the end of
the study was consistent with results from a bioequiva-
lence study in healthy volunteers.11 Accordingly, the
ﬁnal marketed formulation of BBN will be based on the
2:1 ratio and the mean ﬁnal BBN dose, not the doses
used in this clinical trial.
CONCLUSIONS
While these results should be considered preliminary
due to the open-label design, BBN was overall safe
and well tolerated, and it appeared to provide ad-
equate symptom control, in the treatment of opioid-
dependent subjects previously controlled on SLBN for
a minimum of 30 days. There was good adherence to
study medication and favorable patient acceptance of
the buccal formulation. The SLBN-BBN buprenor-
phine conversion ratio was 2:1.
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